PDGFRB and neoplasm: A different, but very promising therapeutic approach, which raised attention during the past decade, uses nanocarriers with a cyclic peptide binding specifically to PDGFRβ (reviewed in [145]) or PDGFRβ affibodies for the specific delivery targeting agents to the tumor site (referred to as “homing”).